bikalutamidi medac 150 mg tabletti, kalvopäällysteinen
medac gesellschaft für klinische spezialpräparate mbh - bicalutamidum - tabletti, kalvopäällysteinen - 150 mg - bikalutamidi
bicalutamide grindeks 50 mg tabletti, kalvopäällysteinen
grindeks joint stock company - bicalutamidum - tabletti, kalvopäällysteinen - 50 mg - bikalutamidi
bicalutamide tad pharma 50 mg tabletti, kalvopäällysteinen
tad pharma gmbh - bicalutamidum - tabletti, kalvopäällysteinen - 50 mg - bikalutamidi
bicalutamide relon chem 50 mg tabletti, kalvopäällysteinen
relonchem ltd - bicalutamidum - tabletti, kalvopäällysteinen - 50 mg - bikalutamidi
bicalutamide relon chem 150 mg tabletti, kalvopäällysteinen
relonchem ltd - bicalutamidum - tabletti, kalvopäällysteinen - 150 mg - bikalutamidi
bicavan 50 mg tabletti, kalvopäällysteinen
avansor pharma oy - bicalutamide - tabletti, kalvopäällysteinen - 50 mg - bikalutamidi
bicavan 150 mg tabletti, kalvopäällysteinen
avansor pharma oy - bicalutamide - tabletti, kalvopäällysteinen - 150 mg - bikalutamidi
casodex 50 mg tabletti, kalvopäällysteinen
laboratoires juvise pharmaceuticals - bicalutamide - tabletti, kalvopäällysteinen - 50 mg - bikalutamidi
casodex 150 mg tabletti, kalvopäällysteinen
laboratoires juvise pharmaceuticals - bicalutamide - tabletti, kalvopäällysteinen - 150 mg - bikalutamidi
xtandi
astellas pharma europe b.v. - enzalutamide - prostatiset kasvaimet - endokriinihoito - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.